Epidermal Growth Factor Receptor Mutations and Their Prognostic Value with Carcinoembryonic Antigen in Pathological T1 Lung Adenocarcinoma

Table 4

Univariate and multivariate analysis results of disease-free and overall survival in patients with T1 lung adenocarcinoma.

Factor	Univariate analysis			Multivariate analysis
	HR	95% CI		HR	95% CI
Disease-free survival
Sex (female versus male)	2.303	1.111–4.775	0.025	1.268	0.583–2.758	0.550
CEA (<2.12 versus ≥2.12)	4.999	2.211–11.302	<0.001	2.877	1.166–7.097	0.022
Tumour size (pT1a versus pT1b versus pT1c)	2.709	1.664–4.411	<0.001	1.454	0.786–2.687	0.233
Histology (AIS and MIA versus IAC)	6.300	2.400–16.540	<0.001	3.204	1.023–10.040	0.046
Lymphatic metastasis (absent versus present)	8.901	3.934–20.139	<0.001	11.201	2.658–47.209	0.001
Pathological stage (stage 0 versus I, II, and IIIA)	2.128	1.430–3.168	<0.001	0.361	0.163–0.800	0.012
Overall survival
Sex (female versus male)	3.472	1.320–9.130	0.012	2.070	0.308–13.899	0.454
Smoking (non versus current/former)	3.235	1.231–8.506	0.017	1.276	0.129–12.663	0.835
CEA (<2.12 versus ≥2.12)	9.200	2.641–32.049	0.001	2.626	0.352–19.583	0.346
EGFR mutation (exon 21 versus exon 19)	6.170	1.162–32.768	0.033	7.153	1.124–45.516	0.037
Tumour size (pT1a versus pT1b versus pT1c)	4.056	2.046–8.039	<0.001	5.793	0.934–35.944	0.059
Histology (AIS and MIA versus IAC)	21.184	2.187–124.759	0.003	36416.346	0.000–3.671E220	0.967
Lymphatic metastasis (absent versus present)	9.309	3.275–26.457	<0.001	14.820	0.172–1276.425	0.236
Pathological stage (stage 0 versus I, II, and IIIA)	2.201	1.319–3.673	0.003	0.448	0.045–4.468	0.494

HR: hazard ratio; CI: confidence interval; CEA: carcinoembryonic antigen; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IAC: invasive adenocarcinoma. .